Mounjaro Injection (2.5mg, 5mg, 7.5mg, 10mg)

Description

The head-to-head data is now in. In the Surmount-5 trial — a direct comparison between tirzepatide and semaglutide — Mounjaro produced 47% greater weight loss than Ozempic. Average weight reduction of 20.2% versus 13.7%. That’s not a marginal difference. For anyone choosing between the two most recognised names in GLP-1 therapy right now, that trial result is the most important piece of information available.

Why Two Receptors Beat One

Ozempic targets GLP-1 receptors. Mounjaro targets both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) simultaneously — which is why Eli Lilly describes it as a “twincretin.” GIP receptors are found not just in the pancreas but in the brain, adipose tissue, and bone. Activating them alongside GLP-1 amplifies the appetite suppression and metabolic effects beyond what GLP-1 stimulation alone produces — more significant reductions in food intake, greater improvements in insulin sensitivity, and more pronounced weight loss across every dose tested.

The SURPASS clinical trial programme confirmed this across five Phase 3 studies: HbA1c reductions of 1.8–2.4% — among the strongest glycaemic control outcomes recorded for any diabetes medication — alongside weight loss that outperformed every comparator including insulin, semaglutide, and insulin degludec.

Understanding the Four Doses

Mounjaro follows a structured escalation approach and each dose in this range has a specific role:

2.5mg — the starting dose only. Not where the therapeutic weight loss and glycaemic effect lives, but where the body adjusts to tirzepatide. Gastrointestinal side effects are most pronounced during initiation, and starting low gives the system time to adapt before escalating. Most people move through this phase within four weeks.

5mg — where meaningful clinical effect begins. The SURPASS data shows 12–17lb average weight loss at 5mg across the trial programme. HbA1c reductions of 1.8–2.1%. For people with milder goals or higher sensitivity to medication, some stay at this level.

7.5mg — the mid-escalation step. Greater weight reduction and glycaemic control than 5mg, with a tolerability profile that’s usually well established by this point.

10mg — where Mounjaro’s full power starts to show. The SURPASS obesity trial recorded average weight reductions of 19.5% at 10mg. HbA1c reductions of 1.7–2.4% in diabetes patients. For most people, this is the dose where the results they came for are most clearly delivered.

Beyond Diabetes — Obstructive Sleep Apnea

An increasingly recognised benefit: tirzepatide is now approved for moderate to severe obstructive sleep apnea in patients with obesity — the first medication to receive this indication. The mechanism isn’t just weight-related airway improvement; there appears to be a direct effect on upper airway function. For people managing both obesity and sleep apnea, this is a meaningful additional reason to consider Mounjaro.

Once Weekly. Pre-Filled Pen. Subcutaneous.

Injected once weekly, any time of day, with or without food. Administered subcutaneously into the abdomen, thigh, or upper arm. Rotate injection sites each week. The pre-filled pen format requires no preparation or mixing — straightforward enough for long-term self-administration.

No Prescription. Worldwide Delivery.

Ordered directly, dispatched fast in completely plain unmarked packaging. No prescription required, tracked to your door anywhere in the world.

Do not use if you or a family member have a history of medullary thyroid carcinoma or MEN2 syndrome. Discontinue at least 2 months before planned pregnancy. Most common side effects are gastrointestinal — nausea, vomiting, diarrhoea — most pronounced during initiation and dose escalation, typically improving with time. Not for use in type 1 diabetes.